Cargando…

Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy

Background: Few studies have explored the association between pancreatic cancer and arterial thromboembolism (aTE). Methods: A total of 838 consecutive patients receiving palliative chemotherapy for pancreatic cancer between 2010 and 2016 were retrospectively enrolled. The clinical characteristics o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Yu-Shin, Chen, Jen-Shi, Chen, Yen-Yang, Lu, Chang-Hsien, Chang, Pei-Hung, Chou, Wen-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267556/
https://www.ncbi.nlm.nih.gov/pubmed/30424491
http://dx.doi.org/10.3390/cancers10110432
_version_ 1783376101741953024
author Hung, Yu-Shin
Chen, Jen-Shi
Chen, Yen-Yang
Lu, Chang-Hsien
Chang, Pei-Hung
Chou, Wen-Chi
author_facet Hung, Yu-Shin
Chen, Jen-Shi
Chen, Yen-Yang
Lu, Chang-Hsien
Chang, Pei-Hung
Chou, Wen-Chi
author_sort Hung, Yu-Shin
collection PubMed
description Background: Few studies have explored the association between pancreatic cancer and arterial thromboembolism (aTE). Methods: A total of 838 consecutive patients receiving palliative chemotherapy for pancreatic cancer between 2010 and 2016 were retrospectively enrolled. The clinical characteristics of patients were analyzed to determine the incidence, risk factors, and survival outcome of aTE in patients with pancreatic cancer. Results: aTE occurred in 42 (5.0%) of 838 patients. Patients with aTE had a worse survival outcome than those without (5.1 months versus 7.8 months, hazard ratio 1.53, 95% confidence interval [CI]: 1.12–2.09). Stage IV disease, high aspartate transaminase level, and comorbidity with hypertension or atrial fibrillation were four independent predictors of aTE. A concise predictive model stratified patients into low (0–1 predictor), intermediate (2 predictors), and high (3–4 predictors) risk groups. The hazard ratios for the comparison of patients in intermediate and high risk groups with those in low risk group were 4.55 (95% CI: 2.31–8.98), and 13.3 (95% CI: 5.63–31.6), respectively. Conclusion: Patients with pancreatic cancer undergoing palliative chemotherapy have an increased risk of aTE. A predictive model showed that patients presented with 3 or 4 predictors had the highest risk for developing aTE.
format Online
Article
Text
id pubmed-6267556
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62675562018-12-03 Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy Hung, Yu-Shin Chen, Jen-Shi Chen, Yen-Yang Lu, Chang-Hsien Chang, Pei-Hung Chou, Wen-Chi Cancers (Basel) Article Background: Few studies have explored the association between pancreatic cancer and arterial thromboembolism (aTE). Methods: A total of 838 consecutive patients receiving palliative chemotherapy for pancreatic cancer between 2010 and 2016 were retrospectively enrolled. The clinical characteristics of patients were analyzed to determine the incidence, risk factors, and survival outcome of aTE in patients with pancreatic cancer. Results: aTE occurred in 42 (5.0%) of 838 patients. Patients with aTE had a worse survival outcome than those without (5.1 months versus 7.8 months, hazard ratio 1.53, 95% confidence interval [CI]: 1.12–2.09). Stage IV disease, high aspartate transaminase level, and comorbidity with hypertension or atrial fibrillation were four independent predictors of aTE. A concise predictive model stratified patients into low (0–1 predictor), intermediate (2 predictors), and high (3–4 predictors) risk groups. The hazard ratios for the comparison of patients in intermediate and high risk groups with those in low risk group were 4.55 (95% CI: 2.31–8.98), and 13.3 (95% CI: 5.63–31.6), respectively. Conclusion: Patients with pancreatic cancer undergoing palliative chemotherapy have an increased risk of aTE. A predictive model showed that patients presented with 3 or 4 predictors had the highest risk for developing aTE. MDPI 2018-11-12 /pmc/articles/PMC6267556/ /pubmed/30424491 http://dx.doi.org/10.3390/cancers10110432 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hung, Yu-Shin
Chen, Jen-Shi
Chen, Yen-Yang
Lu, Chang-Hsien
Chang, Pei-Hung
Chou, Wen-Chi
Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy
title Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy
title_full Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy
title_fullStr Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy
title_full_unstemmed Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy
title_short Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy
title_sort incidence, risk factors, and outcomes of arterial thromboembolism in patients with pancreatic cancer following palliative chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267556/
https://www.ncbi.nlm.nih.gov/pubmed/30424491
http://dx.doi.org/10.3390/cancers10110432
work_keys_str_mv AT hungyushin incidenceriskfactorsandoutcomesofarterialthromboembolisminpatientswithpancreaticcancerfollowingpalliativechemotherapy
AT chenjenshi incidenceriskfactorsandoutcomesofarterialthromboembolisminpatientswithpancreaticcancerfollowingpalliativechemotherapy
AT chenyenyang incidenceriskfactorsandoutcomesofarterialthromboembolisminpatientswithpancreaticcancerfollowingpalliativechemotherapy
AT luchanghsien incidenceriskfactorsandoutcomesofarterialthromboembolisminpatientswithpancreaticcancerfollowingpalliativechemotherapy
AT changpeihung incidenceriskfactorsandoutcomesofarterialthromboembolisminpatientswithpancreaticcancerfollowingpalliativechemotherapy
AT chouwenchi incidenceriskfactorsandoutcomesofarterialthromboembolisminpatientswithpancreaticcancerfollowingpalliativechemotherapy